Drugs / EGFR/IL13Rα2 pool-CAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07544992 | Dec 2026 → Nov 2031 expected | IDH-wildtype glioblastoma, astrocytoma, IDH-mutant, grade 4 | City of Hope Medical Center | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EGFR/IL13Rα2 pool-CAR T cells | “EGFR/IL13Rα2 pool-CAR T cells are a type of CAR T cell therapy.” NCT07544992 ↗ |
| Modality | Cell therapy | “EGFR/IL13Rα2 pool-CAR T cells are a type of CAR T cell therapy.” NCT07544992 ↗ |
| Route | Other | “Given via ICT and/or ICV catheter” NCT07544992 ↗ |
| Target | EGFR | “locoregional administration of autologous anti-EGFR/anti-IL13Rα2 CAR T-cells” NCT07544992 ↗ |